Catriona Jamieson, M.D., Ph.D., Professor of Medicine, University of California, San Diego Health Moores Cancer Center, addresses a common myth about clinical trials.
Catriona Jamieson, M.D., Ph.D., Professor of Medicine, University of California, San Diego Health Moores Cancer Center, addresses a common myth about clinical trials.
People often think clinical trials benefit doctors and science more than they help the people who participate in them. Clinical trials are actually better, more advanced care.
To be able to get through the Food and Drug Administration's regulations today, the burden of proof to be able to do a clinical trial is much higher than in the past. The likelihood of responding well in a safety, tolerability and proof-of-concept study is much better, as well as trial studies in later phases.
Traditional Definition of ‘High-Risk’ in Patients With CLL and SLL Outdated, Needs to be Revisited
December 7th 2020In an interview with CURE®, Dr. Jan A. Burger discusses how the results of two phase 3 studies could help redefine what constitutes as low or high risk in patients with CLL or SLL.
Read More
To gain a better understanding of the issues faced by geriatric patients with cancer, and to determine how much of a role nutrition plays in outcomes, Dr. Grant Williams, a geriatrician oncologist and assistant professor at the University of Alabama, Birmingham, worked with colleagues to create a patient-reported assessment tool that bridges the knowledge gap in this patient population.
Read More